<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">
Log In

SmartTRAK Life Sciences News and Analysis Blog

3 min read

Enthesis Reformation and the Science of Bone-to-Tendon Healing

By Andy Knapik on 3/26/25 9:25 AM

SmartTRAK spotlights Tetrous in an interview at AAOS 2025 in San Diego. 

Andy Carter, Chief Technology Officer and Founder of Tetrous, discusses the company’s novel approach to addressing Enthesis Failure Syndrome in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting in San Diego. 

To learn more about Tetrous and its novel technology, listen to the following video. (21:42 min.) A link to download the transcript of the interview is also provided below. 

 

Hey everybody, it's Andy Knapik, live here at AAOS 2025 in San Diego. Today I'm joined here with a friend, colleague, and someone I've known now for, I guess a couple years, Andy Carter, Founder, Chief Technology Officer of a company called Tetrous, which is really some exciting biologic technology. So I just brought him along. We're going to chat a little bit about it. So Andy, why don't you just tell everybody what it is about Tetrous and what you guys do and why it's so great.

Andy Carter: Thanks for the opportunity. It's a great topic to talk about and I really, really love it. So we started Tetrous a couple of years ago. We spun it out of Theracell, the company that we sold to, ISTO Biologics. They're doing great and taking the technology in the spine and doing various things. But along the way, I read quite a few papers about how demineralized bone matrix materials could influence enthesis repair. And that's getting back to sports medicine, which is my roots and well, my real passion. I looked at these papers and they basically showed that demineralized bone matrix materials could influence the enthesis to heal. A tendon, the enthesis, is the bit between the tendon and the bone. It's the junction. It's how you get load transfer between rigid bone and flexible tendon. It's a biological structure that's very exquisite and unique. You look at the histology and the biologists go into raptures and "wows" about it and whatever.

The fundamentals are that you've got collagen fibers going from the bone through into the tendon. That's what gives you the strength. You see them in the histology with Sharpey's fibers. If you just reattach tendon to bone, you just get scar tissue. Scar tissue is not as strong. Basically, it pulls out and thins and fails with time. So part of the reason that we see so many problems with rotator cuff repair is that nobody's doing anything to heal the enthesis. There was this literature out there saying, ‘Hey, you can use DBM for this,’ but none of the papers showed it in any way that was something that you could see a surgeon being able to use-

Right, a practical form.

AC: There's one group, guys I know very well had used DBM powder. Now DBM powder, you can do it in a rat study and show that it works, but that's not a product. So what we were able to do, one of the clever things about the technology that we developed at Theracell, the fiber technology is, it allows us to ....

Click the button below to download and read the complete transcript of SmartTRAK's interview with Andy Carter, founder and CTO of Tetrous, conducted by Andy Knapik, SmartTRAK Senior Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies.Download the Transcript


SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.

Continue Reading
3 min read

Meet The Expert: Elizabeth Anderson, Senior Analyst, Biologics

By Thomas Wallick on 3/26/25 8:00 AM

We are pleased to announce that Elizabeth Anderson has joined the team at SmartTRAK as Senior Analyst, Biologics. Before joining SmartTRAK, Elizabeth got her start at Healthpoint in Texas and has since worked in various roles with several of the top companies in the biological space, including Smith+Nephew and Organogenesis. 

Meet Elizabeth Anderson:

What is your role with SmartTRAK? My role with SmartTRAK will be as a Senior Analyst for the Biologics module.

What do you like about SmartTRAK? I have been using SmartTRAK since the platform started. My favorite feature is the ability to have information relevant to both the commercial and clinical sides of the market in one place. 

What is something special or unique you bring to SmartTRAK subscribers?
The majority of my roles have been responsible for market research and business intelligence. I have extensive experience combining primary and secondary data to get a full picture of the market.

What do you think the biggest promise of medical technology (in your area) is?  In the Biologics space, it isn't easy to choose just one. A lot of research is looking into the ability to impregnate matrices or grafts with growth factors or cell types that a patient may be missing based on their pathophysiology. 

How will it change everything? This would allow clinicians to tailor their tx specifically, giving the patient what is needed to heal. Of course, this hinges on the proper diagnostics, but I think it is where we are headed.

What are your favorite online websites or resources that you check every day? Of course, I stay up to date with SmartTrak and LinkedIn, my go-to sources, but I also monitor the CMS website in this space.

How do you keep your medical device research skills sharp? I keep my skills sharp by attending conferences, reading published clinical studies, and talking to clinicians on the front lines.

What was the last presentation you gave and to who, about what?  My last presentation was a forecast model for a new product launching clinical trials to enter the US market. It was for a US Business Development Director for an OUS manufacturer.

What was the last show you binge-watched? The last show I binge-watched was the limited series American Primeval on Netflix. It is a good story.

What is your life like outside of SmartTRAK?
Outside of SmartTRAK, I run a lot, tend to my senior dog, and try to teach myself new baking skills. I have backed off a lot of the long-distance running but still do a few endurance events.

If you'd like to learn more about SmartTRAK and how it can increase proficiency, improve productivity and reduce costs for your company, or if you would like to meet with Elizabeth, just click the button below.Learn More

Continue Reading
2 min read

LCD Uncertainty Bringing Disruption to CAMPs

By Susan Paquette on 3/25/25 9:45 AM

CAMPs 2025 meeting highlights the use of CAMPs in all sites of care.

SmartTRAK reports the latest news and trends in cellular, acellular and matrix-like products (CAMPs) from the CAMPs 2025 Wound Care Summit held February 28 to March 2 in Fort Lauderdale, Florida. Hosted by the Journal of Wound Care (JWC), CAMPs 2025 showcased new clinical research, consensus guidelines and presentations supporting the use of CAMPs amid uncertainties in reimbursement for these products in the US Market for Skin Substitutes.

The subjects discussed in this downloadable SmartTRAK Perspective article include:

  • The Broad Use of CAMPs
    • Sessions at CAMPs 2025 supported the broad use of CAMPs, including applications for diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) as well as those for limb salvage, acute care, tunneling wounds, Mohs surgery, trauma, burns and pressure ulcers (PrUs). SmartTRAK expects the use of CAMPs to ... (read more)
  • LCD Discussions Taking Center Stage
    • With the implementation of the MAC LCDs delayed until April 13th, a prevailing question among attendees at the conference was whether the LCDs would actually be implemented or further delayed. SmartTRAK spoke with clinicians and industry representatives to obtain their views on the LCDs and ... (read more)
  • Market Disruption – 2025 Earnings Projections
    • For public companies providing skin substitutes to the market, uncertainty was a major theme in their 2025 guidance SmartTRAK  summarizes comments from companies that mentioned the LCD in their 2025 revenue projections ... (read more)

Although a significant amount of discussion with clinicians and industry focused on revising the reimbursement methodology for skin substitutes, companies are still moving forward with clinical studies. SmartTRAK is currently tracking 26 clinical trials for DFUs and VLUs, as mentioned earlier and ...

To find out more about news and trends from CAMPs 2025, just click the button below to download the complete market perspective article "LCD Uncertainty Bringing Disruption to CAMPs" by Susan Paquette, VP & General Manager, Wound.


SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.

Topics: Wound Care
Continue Reading
3 min read

Artificial Intelligence in Wound Diagnostics: Four Companies to Watch in 2025

By Kris Flinn on 3/25/25 9:30 AM

SmartTRAK highlights four wound diagnostics companies utilizing artificial intelligence to watch in 2025.

Artificial intelligence (AI) is becoming increasingly ubiquitous in our personal and professional lives. AI is already being applied in healthcare in areas such as image analysis, personalized treatments and predictive care. Future potential applications include improved analysis of healthcare data, optimizing medication doses and enhancing patient education. The challenges of AI are also widely discussed, with ethical and legal concerns combined with a general worry that patient care could become dehumanized and distanced from healthcare professionals.

In this downloadable article, SmartTRAK identifies and discusses the following four diagnostic companies facilitating AI that should be watched in 2025:

  • eKare
    • Wound assessment company eKare has been at the forefront of the conversation around AI in wound care. The core functionality of inSight, a 3D digital wound imaging system, includes AI aspects such as ... (read more)
  • Mimosa Diagnostics
    • Canadian tissue oximetry company Mimosa Diagnostics primarily implements AI to enhance the usability of its Mimosa Pro device, which uses ... (read more)
  • Spectral AI
    • Texas-based Spectral AI has undertaken significant fundraising over recent years. Over $150 million of Biomedical Advanced Research and Development Authority (BARDA) funding since 2013 has facilitated ... (read more)
  • Swift Medical
    • Toronto-based Swift Medical saw a significant change in 2024. New leadership was announced in June as Dwayne Sansone and Stratos Davlos assumed the roles of CEO and CTO, respectively. The company received ... (read more)

The benefits of AI in wound care include accuracy and efficiency of wound characterization, remote monitoring, personalized care and increased accessibility to wound care ...

To find out more about how these companies are incorporating AI, just click the button below to download the complete market outlook article "Artificial Intelligence in Wound Diagnostics: Four Companies to Watch in 2025" by Kris Flinn, SmartTRAK General Manager, Wound.Get the Article

Continue Reading
2 min read

Spine Market Shake-Up: Trends, Drivers and What’s Next

By Elise Wolf on 3/18/25 9:30 AM

SmartTRAK delves into recent spinal implant divestitures.

The global Spinal Implant Market has seen an increasing number of divestitures in recent years. Large strategics are streamlining their portfolios, while private equity firms and specialized manufacturers are capitalizing on the opportunity to acquire divested assets. In this article, SmartTRAK explores the key drivers behind these divestitures, notable transactions and the broader implications for the industry, including:

  • Recent Divestitures from Key Players
    • In January, Stryker (SYK) announced a definitive agreement to sell its US spinal implants business to the Viscogliosi Brothers (VB), a New York-based investment firm focused on neuro and musculoskeletal technologies. VB Spine is set to become ... (read more)
  • Why the Shake-ups? 
    • The Spine Hardware Market is characterized as a very SKU-heavy business with little differentiation among implants, making it expensive and requiring savvy and specialized operations to ensure profitability. Market-leading strategics, Medtronic (MDT) and Globus (GMED) are acquiring ... (read more)
  • Focus on Interventional Market
    • With ZBH and SYK exiting the spinal fusion space altogether, other companies are targeting adjacent high-growth markets, where there is a much larger population of chronic low back pain (CLBP) patients to treat in lieu of fusion. Post divestiture, SYK will retain ... (read more)
  • Continued Evolution Expected
    • Consolidation and specialization in the Spine Market could lead to improved product quality, better integration of new technologies and enhanced patient outcomes. SmartTRAK expects the Spine Market 
      will ...(read more)

Curious about the latest transactions and trends in the Spine Market and the broader implications for the industry? Click the button below to download the complete market outlook article, "Spine Market Shake-Up: Trends, Drivers and What’s Next" by Elise Wolf, SmartTRAK VP& GM, Orthopedics & Quality.Get the Article


SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.
Continue Reading
3 min read

CG 2025 Musculoskeletal Conference: Spotlight on Doron Therapeutics

By Sharon O'Reilly on 3/11/25 11:40 AM

SmartTRAK spotlights Doron Therapeutics in an interview with CEO Alessandra Pavesio at CG 2025 Musculoskeletal Conference in San Diego. 

Alessandra Pavesio, CEO of Doron Therapeutics, discusses the company, recent milestones and MOTYS, the company’s placental-derived injectable therapeutic for osteoarthritis, in an interview with   SmartTRAK  at the Canaccord Genuity (CG) 2025 Musculoskeletal Conference in San Diego, March 10, 2025.

To find out more, watch the following video (4:27 min). A link to a transcript of the interview is also provided below. 


SmartTRAK: Hi, this is Sharon O'Reilly. I'm at the Canaccord Conference before the 2025 AAOS, and I ran into Alessandra Pavesio, who's so excited about her company, Doron Therapeutics.

So, Alessandra, why don't you tell us a little bit about the company and some of the exciting new developments.

Alessandra Pavesio: It's always great to see you, Sharon. I love bumping into you and having some really good news to deliver. First of all, what is Doron Therapeutics? It's a management-led spin-off. We really were passionate about a technology that we've developed with Bioventus, and when Bioventus divested from this program for financial considerations, we were able to negotiate a very favorable deal to actually set up a spin-off company and go raise private capital to invest in the program.

The good news is that, yes, we've set up a company. Yes, we have raised private capital. And so now we are really up and running and getting ready to start a Phase III study.

Big milestone that we've accomplished is that we've been recognized by FDA as an RMAT therapy. RMAT means Regenerative Medicine Advanced Therapy. As such, that means attention from senior officials at FDA that are really partnering with you to get this product to market for the patients that we serve. Super excited.

SmartTRAK: Tell us about the product.

AP: So our lead program is called MOTYS. It's placental-derived injectable therapeutic. It's a biological drug that ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with Doron Therpeutics' CEO Alessandro Pavesio, conducted by Sharon O'Reilly, SmartTRAK Founder and CEO.Download the Transcript

Continue Reading
2 min read

Bone Replacement Trends for 2025

By Erin Dorgan on 3/10/25 2:54 PM

SmartTRAK will be attending AAOS 2025 this week. Join us at AAOS to explore our solution and discuss our roadmap for expanding into other orthopedic markets. Learn more about our Brand Tracker here or schedule time to Meet with Us at the show!

Topics: Orthopedics
Continue Reading
3 min read

The Future of Arthroscopic Technologies in 2025 and Beyond

By Andy Knapik on 3/4/25 9:30 AM

SmartTRAK highlights the key trends in the US Arthroscopic Technologies Market that will drive growth in 2025 and beyond.

The Arthroscopic Technologies (AT) Market is poised for significant advancements as we move through 2025 and beyond. With an anticipated compound annual growth rate (CAGR) of 4.3%, the US AT market is projected to rapidly expand by 2028. This growth is driven by technological innovations and the increasing prevalence of minimally invasive procedures.

In this downloadable market outlook article, SmartTRAK highlights the top technology trends to watch in 2025 that are shaping the future of AT, including:

  • Continued Evolution in Arthroscopic Visualization
    • The arthroscopic visualization segment is undergoing a transformation driven by technological advancements and shifting market dynamics, increasing at ... (read more)
  • Growth in Bundled Solutions
    • In the AT space, consumables such as resection tools, radiofrequency (RF) devices and fluid management products are significant revenue drivers. SmartTRAK estimates ... (read more)
  • ASC Shift Driving Demand for All-in-One Solutions
    • The growth of ASCs has heightened the demand for all-in-one solutions, enabling sports medicine companies to ... (read more)
  • Growing Interest in Direct Display Communications
    • SmartTRAK expects to see growing interest in direct display communications in 2025. Building on these advancements in integrated arthroscopic visualization, the next frontier is  ... (read more)
  • Challenges and Future Outlook
    • While advancements in arthroscopic technologies are progressing, they remain ... (read more)

Want to stay ahead of the curve in arthroscopic technologies for 2025 and beyond? Click the button below to download Andy Knapik's market outlook article, "The Future of Arthroscopic Technologies in 2025 and Beyond." As SmartTRAK’s Sr Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies, Andy provides an informative analysis of the latest market shifts, including the challenges ahead for the industry.Get the Article

Continue Reading
2 min read

Game-Changing Innovations in Orthobiologics for 2025 and Beyond

By Emily Meng on 2/25/25 9:30 AM

SmartTRAK highlights game-changing trends in orthobiologics for 2025 and beyond.

SmartTRAK highlights trends to watch in 2025 and beyond that will impact the US OrthoBiologics Market, which is projected to achieve a CAGR of 5.1% by 2028E. The OrthoBio Market has made significant strides over the past few years, primarily driven by breakthroughs in new technical approaches, product development and strong commercial execution.

In this downloadable article, SmartTRAK explores the current state of orthobiologic implants, focusing on two key segments, the Cartilage Replacement and Soft Tissue Replacement Markets, including:

  • Emerging Biomaterials & Technologies – Products in Play for 2025 and Beyond
    • Cartilage Replacement
    • Soft Tissue Replacement
      • Soft Tissue Augmentation
      • Knee Ligament Replacement
  • Clinical Trial Spotlights – Products on Deck for 2025 and Beyond
    • Cartilage
    • Soft Tissue Replacement
        • Soft Tissue Augmentation
        • Knee Ligament Replacement

The article examines, in depth, companies that are in the line-up with clinical trials and the recent technological breakthroughs and regulatory milestones shaping the Orthobiologics market ...

Curious about the latest innovations and trends in the Orthobiologics Market for 2025?  Click the button below to download the complete market outlook article, "Game-Changing Innovations in Orthobiologics for 2025 and Beyond" by SmartTRAK's Emily Meng.Get the Article

Continue Reading
2 min read

Feel the Pressure: Compression Trends for 2025

By Jay Merkel on 2/19/25 9:33 AM

SmartTRAK highlights the key trends in the US Compression Therapy market that will drive growth over the next few years.

In the US Market for Compression Devices, SmartTRAK projects revenues to reach a 5-year CAGR of +6.2%. In 2025, SmartTRAK expects mid-single-digit growth to continue and sees three key trends that will help drive growth over the next several years. These include:

  • Expanding Reimbursement for Lymphedema Products 
    • One of the biggest growth drivers for compression therapies in 2025 is expanding reimbursement for the treatment of lymphedema. With more than three million lymphedema patients estimated in the US alone, SmartTRAK expects ... (read more)
  • Improving Ease of Use for Compression Garments
    • SmartTRAK expects several companies to develop or refine compression garments in the years ahead with a focus on improving ease of use. With the growing number of patients having access to compression garments day and night, it’s become even more important for ... (read more)
  • Dynamic Compression Innovations Improving Portability
    • In the world of dynamic compression, portability is the name of the game and SmartTRAK expects to see ... (read more)

Want to stay ahead of the curve in the US compression device market for 2025 and beyond? Industry trends, regulatory changes and new reimbursement codes are shaping the future—are you prepared?

Click the button below to download Jay Merkel’s market outlook article, "Feel the Pressure: Compression Trends for 2025." As SmartTRAK’s senior analyst, Wound, Jay provides an informative analysis of the latest market shifts, including new compression codes and major code revisions set to take effect on April 1, 2025.

Get the Article

Topics: Wound Care
Continue Reading
  • There are no suggestions because the search field is empty.

Recent Articles